Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Ofer Zimmerman; Berenice Rösler; Christa S. Zerbe; Lindsey B. Rosen; Amy P. Hsu; Gulbu Uzel; Alexandra F. Freeman; Elizabeth P. Sampaio; Sergio D. Rosenzweig; Hye Sun Kuehn; Tiffany Kim; Kristina M. Brooks; Parag Kumar; Xiaowen Wang; Mihai G. Netea; Frank L. Van De Veerdonk; Steven M. Holland

doi:10.1093/ofid/ofx202

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Ofer Zimmerman, Berenice Rösler, Christa S. Zerbe, Lindsey B. Rosen, Amy P. Hsu, Gulbu Uzel, Alexandra F. Freeman, Elizabeth P. Sampaio, Sergio D. Rosenzweig, Hye Sun Kuehn, Tiffany Kim, Kristina M. Brooks, Parag Kumar, Xiaowen Wang, Mihai G. Netea, Frank L. Van De Veerdonk, Steven M. Holland

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.

Original language	English
Article number	ofx202
Journal	Open Forum Infectious Diseases
Volume	4
Issue number	4
DOIs	https://doi.org/10.1093/ofid/ofx202
State	Published - 2017

Keywords

STAT1
coccidiomycosis
dermatophytosis
gain of function
ruxolitinib

Access to Document

10.1093/ofid/ofx202

Cite this

Zimmerman, O., Rösler, B., Zerbe, C. S., Rosen, L. B., Hsu, A. P., Uzel, G., Freeman, A. F., Sampaio, E. P., Rosenzweig, S. D., Kuehn, H. S., Kim, T., Brooks, K. M., Kumar, P., Wang, X., Netea, M. G., Van De Veerdonk, F. L., & Holland, S. M. (2017). Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease. Open Forum Infectious Diseases, 4(4), Article ofx202. https://doi.org/10.1093/ofid/ofx202

@article{a128ed94671f495fbafea2619510cafa,

title = "Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease",

abstract = "Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.",

keywords = "STAT1, coccidiomycosis, dermatophytosis, gain of function, ruxolitinib",

author = "Ofer Zimmerman and Berenice R{\"o}sler and Zerbe, {Christa S.} and Rosen, {Lindsey B.} and Hsu, {Amy P.} and Gulbu Uzel and Freeman, {Alexandra F.} and Sampaio, {Elizabeth P.} and Rosenzweig, {Sergio D.} and Kuehn, {Hye Sun} and Tiffany Kim and Brooks, {Kristina M.} and Parag Kumar and Xiaowen Wang and Netea, {Mihai G.} and {Van De Veerdonk}, {Frank L.} and Holland, {Steven M.}",

year = "2017",

doi = "10.1093/ofid/ofx202",

language = "English",

volume = "4",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

number = "4",

}

Zimmerman, O, Rösler, B, Zerbe, CS, Rosen, LB, Hsu, AP, Uzel, G, Freeman, AF, Sampaio, EP, Rosenzweig, SD, Kuehn, HS, Kim, T, Brooks, KM, Kumar, P, Wang, X, Netea, MG, Van De Veerdonk, FL & Holland, SM 2017, 'Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease', Open Forum Infectious Diseases, vol. 4, no. 4, ofx202. https://doi.org/10.1093/ofid/ofx202

TY - JOUR

T1 - Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

AU - Zimmerman, Ofer

AU - Rösler, Berenice

AU - Zerbe, Christa S.

AU - Rosen, Lindsey B.

AU - Hsu, Amy P.

AU - Uzel, Gulbu

AU - Freeman, Alexandra F.

AU - Sampaio, Elizabeth P.

AU - Rosenzweig, Sergio D.

AU - Kuehn, Hye Sun

AU - Kim, Tiffany

AU - Brooks, Kristina M.

AU - Kumar, Parag

AU - Wang, Xiaowen

AU - Netea, Mihai G.

AU - Van De Veerdonk, Frank L.

AU - Holland, Steven M.

PY - 2017

Y1 - 2017

N2 - Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.

AB - Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.

KW - STAT1

KW - coccidiomycosis

KW - dermatophytosis

KW - gain of function

KW - ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85048934575&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofx202

DO - 10.1093/ofid/ofx202

M3 - Article

AN - SCOPUS:85048934575

SN - 2328-8957

VL - 4

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 4

M1 - ofx202

ER -

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this